MIRM 43.69 (+3.8%)
US6047491013BiotechnologyBiotechnology

Mirum Pharmaceuticals (MIRM) Stock Highlights

43.69 | +3.8%
2024-11-21 02:58:07
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Statistics

Range Today
41.4 44.12
Volume Today 450.9K
Range 1 Year
23.14 48.89
Volume 1 Year 146.06M
Range 3 Year
12.82 48.89
Volume 3 Year 330.09M
Range 10 Year
6.513 48.89
Volume 10 Year 411.98M

Highlights

Market Capitalization 2B (mid)
Floating Shares 36.01M
Current Price 43.69
Price To Earnings -17.43
Price To Revenue 7.72
Price To Book 8.72
Earnings Per Share -2.36
Payout Ratio 0%

Performance

Latest +3.8%
1 Month +11.28%
3 Months +3.7%
6 Months +80.16%
1 Year +36.23%
3 Years +176.52%
5 Years +496.04%
10 Years +236.08%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.